|
1
|
Pasechnikov V, Chukov S, Fedorov E,
Kikuste I and Leja M: Gastric cancer: Prevention, screening and
early diagnosis. World J Gastroenterol. 20:13842–13862. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shi J, Qu YP and Hou P: Pathogenetic
mechanisms in gastric cancer. World J Gastroenterol.
20:13804–13819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baer C, Claus R and Plass C: Genome-wide
epigenetic regulation of miRNAs in cancer. Cancer Res. 73:473–477.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bouyssou JM, Manier S, Huynh D, Issa S,
Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer
metastasis. Biochim Biophys Acta. 1845:255–265. 2014.PubMed/NCBI
|
|
6
|
Matuszcak C, Haier J, Hummel R and Lindner
K: MicroRNAs: Promising chemoresistance biomarkers in gastric
cancer with diagnostic and therapeutic potential. World J
Gastroenterol. 20:13658–13666. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu Y, An Y, Wang Y, Zhang C, Zhang H,
Huang C, Jiang H, Wang X and Li X: miR-101 inhibits autophagy and
enhances cisplatin-induced apoptosis in hepatocellular carcinoma
cells. Oncol Rep. 29:2019–2024. 2013.PubMed/NCBI
|
|
8
|
Wang L, Li L, Guo R, Li X, Lu Y, Guan X,
Gitau SC, Wang L, Xu C, Yang B and Shan H: miR-101 promotes breast
cancer cell apoptosis by targeting janus kinase 2. Cell Physiol
Biochem. 34:413–422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang X, Liu Y, Zeng L, Yu C, Hu Z, Zhou Q
and Yang Z: miR-101 Inhibits the G1-to-S phase transition of
cervical cancer cells by targeting Fos. Int J Gynecol Cancer.
24:1165–1172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang JG, Guo JF, Liu DL, Liu Q and Wang
JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small
cell lung cancer through directly targeting enhancer of zeste
homolog 2. J Thorac Oncol. 6:671–678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J,
Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, et al:
MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation,
invasion and stem cell-like phenotype of aggressive endometrial
cancer cells. Oncotarget. 5:6049–6062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo F, Cogdell D, Hu L, Yang D, Sood AK,
Xue F and Zhang W: MiR-101 suppresses the epithelial-to-mesenchymal
transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol
Rep. 31:2021–2028. 2014.PubMed/NCBI
|
|
13
|
Lin X, Guan H, Li H, Liu L, Liu J, Wei G,
Huang Z, Liao Z and Li Y: miR-101 inhibits cell proliferation by
targeting Rac1 in papillary thyroid carcinoma. Biomed Rep.
2:122–126. 2014.PubMed/NCBI
|
|
14
|
He XP, Shao Y, Li XL, Xu W, Chen GS, Sun
HH, Xu HC, Xu X, Tang D, Zheng XF, et al: Downregulation of miR-101
in gastric cancer correlates with cyclooxygenase-2 overexpression
and tumor growth. FEBS J. 279:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT,
Xia YJ, Ye ZY and Tao HQ: MicroRNA-101 is down-regulated in gastric
cancer and involved in cell migration and invasion. Eur J Cancer.
46:2295–2303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu SQ, Yu HC, Gong YZ and Lai NS:
Quantitative measurement of HLA-B27 mRNA in patients with
ankylosing spondylitis–correlation with clinical activity. J
Rheumatol. 33:1128–1132. 2006.PubMed/NCBI
|
|
17
|
Chang Z, Huo L, Li K, Wu Y and Hu Z:
Blocked autophagy by miR-101 enhances osteosarcoma cell
chemosensitivity in vitro. Scientific World Journal.
2014:7947562014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu L, Guo J, Yu L, Cai J, Gui T, Tang H,
Song L, Wang J, Han F, Yang C, et al: miR-101 regulates expression
of EZH2 and contributes to progression of and cisplatin resistance
in epithelial ovarian cancer. Tumour Biol. 35:12619–12626. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bu Q, Fang Y, Cao Y, Chen Q and Liu Y:
Enforced expression of miR-101 enhances cisplatin sensitivity in
human bladder cancer cells by modulating the cyclooxygenase-2
pathway. Mol Med Rep. 10:2203–2209. 2014.PubMed/NCBI
|
|
20
|
Shibuya M: VEGF-VEGFR signals in health
and disease. Biomol Ther (Seoul). 22:1–9. 2014. View Article : Google Scholar
|
|
21
|
Goel HL and Mercurio AM: VEGF targets the
tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang X, Xu F, Li X, Ma C, Zhang Y and Xu
W: VEGF signal system: The application of antiangiogenesis. Curr
Med Chem. 21:894–910. 2014. View Article : Google Scholar
|
|
23
|
Wang L, Li HG, Wen JM, Peng TS, Zeng H and
Wang LY: Expression of CD44v3, erythropoietin and VEGF-C in gastric
adenocarcinomas: Correlations with clinicopathological features.
Tumori. 100:321–327. 2014.PubMed/NCBI
|
|
24
|
Cao W, Fan R, Yang W and Wu Y: VEGF-C
expression is associated with the poor survival in gastric cancer
tissue. Tumour Biol. 35:3377–3383. 2014. View Article : Google Scholar
|
|
25
|
Cho HJ, Kim IK, Park SM, Baek KE, Nam IK,
Park SH, Ryu KJ, Choi J, Ryu J, Hong SC, et al: VEGF-C mediates
RhoGDI2-induced gastric cancer cell metastasis and cisplatin
resistance. Int J Cancer. 135:1553–1563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li D, Xie K, Ding G, Li J, Chen K, Li H,
Qian J, Jiang C and Fang J: Tumor resistance to anti-VEGF therapy
through up-regulation of VEGF-C expression. Cancer Lett. 346:45–52.
2014. View Article : Google Scholar
|
|
27
|
Hua KT, Lee WJ, Yang SF, Chen CK, Hsiao M,
Ku CC, Wei LH, Kuo ML and Chien MH: Vascular endothelial growth
factor-C modulates proliferation and chemoresistance in acute
myeloid leukemic cells through an endothelin-1-dependent induction
of cyclooxygenase-2. Biochim Biophys Acta. 1843:387–397. 2014.
View Article : Google Scholar
|
